摘要
免疫疗法导致了一些恶性肿瘤治疗的范式转变,为一些晚期癌症患者提供了长期持久的反应。越来越多的研究已经确定了免疫系统与关键的致癌性生长因子通路之间的联系。磷酸肌醇3-激酶(PI3K)-AKT-mTOR级联在癌症中经常被高度活化,并且在包括肿瘤生长和存活在内的许多细胞过程中起着不可或缺的作用,并且可能成为对治疗的抗性的基础。在这篇综述中,我们首先总结了该途径抑制剂最初研究的两项关键性知识,包括免疫相关不良事件的概况,如结肠炎,转氨酶和肺炎,以及大多数靶向药物的感染发生率增加PI3K-AKT-mTOR途径。然后我们讨论了我们对该通路在肿瘤微环境中的作用以及对先天和适应性免疫反应的调节的理解的最新进展,并提出了与PI3K-网络抑制剂和癌症免疫疗法的协同组合策略。
关键词: PI3K抑制剂,免疫疗法,联合疗法,PI3K途径,微环境,癌症。
Current Cancer Drug Targets
Title:The PI3K Pathway at the Crossroads of Cancer and the Immune System: Strategies for Next Generation Immunotherapy Combinations
Volume: 18 Issue: 4
关键词: PI3K抑制剂,免疫疗法,联合疗法,PI3K途径,微环境,癌症。
摘要: Immunotherapy has led to a paradigm shift in the treatment of some malignancies, providing long-term, durable responses for a subset of patients with advanced cancers. Increasingly, research has identified links between the immune system and critical oncogenic growth factor pathways. The phosphoinositide 3-kinase (PI3K)-AKT-mTOR cascade is frequently hyperactivated in cancer, and plays an integral role in many cellular processes including tumour growth and survival and can underlie resistance to therapies.
In this review, we first summarize two key learnings from the initial studies of inhibitors of this pathway, including the profile of immune-related adverse events such as colitis, transaminitis and pneumonitis and the increased incidence of infections with the majority of agents that target the PI3K-AKT-mTOR pathway. We then discuss recent advances in our understanding of the role of this pathway in the tumour micro-environment, and in the regulation of innate and adaptive immune responses, and propose synergistic combination strategies with PI3K-network inhibitors and cancer immunotherapy.
Export Options
About this article
Cite this article as:
The PI3K Pathway at the Crossroads of Cancer and the Immune System: Strategies for Next Generation Immunotherapy Combinations, Current Cancer Drug Targets 2018; 18 (4) . https://dx.doi.org/10.2174/1568009617666170927114440
DOI https://dx.doi.org/10.2174/1568009617666170927114440 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
Role of Immune and Genotoxic Response Biomarkers in Tumor Microenvironment in Cancer Diagnosis and Treatment
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process of exploring and investigating the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
The Impact of Cancer Neuroscience on Novel Brain Cancer Treatment
Brain cancer remains one of the most challenging malignancies due to its complexity and resistance to conventional therapies. Recent advancements in cancer neuroscience have transformed our understanding of the brain's tumor microenvironment, offering promising insights into novel treatments. By studying the intricate interactions between cancer cells and the nervous system, ...read more
Unraveling the Tumor Microenvironment and Potential Therapeutic Targets: Insights from Single-Cell Sequencing and Spatial Transcriptomics
This special issue will focus on unraveling the complexities of the tumor microenvironment (TME) and identifying key biomarkers for potential therapeutic targets using advanced multi-omics techniques, such as single-cell sequencing and spatial transcriptomics. We seek original research and comprehensive reviews that investigate the heterogeneity and dynamics of the TME, emphasizing ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MicroRNA-21: From Cancer to Cardiovascular Disease
Current Drug Targets Role of MicroRNAs in Treatment Response in Prostate Cancer
Current Cancer Drug Targets Aquaporins and Glia
Current Neuropharmacology The Alcoholic Bark Extract of <i>Terminalia Arjuna</i> Exhibits Cytotoxic and Cytostatic Activity on Jurkat Leukemia Cells
Venoms and Toxins The Endothelin Axis as Therapeutic Target in Human Malignancies: Present and Future
Current Pharmaceutical Design Lipoxygenase (LOX) Pathway: A Promising Target to Combat Cancer
Current Pharmaceutical Design Hsp90: A Novel Target for Cancer Therapy
Current Topics in Medicinal Chemistry Purinergic Signaling and Energy Homeostasis in Psychiatric Disorders
Current Molecular Medicine How to Inhibit Telomerase Activity for Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Lectins in Human Cancer: Both a Devil and an Angel?
Current Protein & Peptide Science Nutraceuticals and "Repurposed" Drugs of Phytochemical Origin in Prevention and Interception of Chronic Degenerative Diseases and Cancer
Current Medicinal Chemistry Snake Venom L-Amino Acid Oxidases: Some Consideration About their Functional Characterization
Protein & Peptide Letters Marine Natural Products with High Anticancer Activities
Current Medicinal Chemistry New Quinoline Based Sulfonamide Derivatives: Cytotoxic and Apoptotic Activity Evaluation Against Pancreatic Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry RAS/RAF/MEK Inhibitors in Oncology
Current Medicinal Chemistry Cell Bystander Effect Induced by Radiofrequency Electromagnetic Fields and Magnetic Nanoparticles
Current Nanoscience EDITORIAL [Hot topic: New Therapeutic Advances and Perspectives in Tumour Angiogenesis (Guest Editor: Eddy Pasquier)]
Current Cancer Drug Targets A Systemic Approach to Cancer Treatment: Tumor Cell Reprogramming Focused on Endocrine-Related Cancers
Current Medicinal Chemistry MicroRNA and Cancer: Tiny Molecules with Major Implications
Current Genomics Crossed Cerebellar Diaschisis in Alzheimer’s Disease
Current Alzheimer Research